WHENFebruary 10, 2018 @ 8:20am - 6:00pm
WHEREHilton San Diego/Del Mar, 15575 Jimmy Durante Blvd, Del Mar, CA
INFOSABPA is excited to bring you the 2nd Frontiers in Therapeutics and Diagnostics (FTD) Forum. This forum will cover three hot topics, including liquid biopsy, gene editing and artificial intelligence. We are honored to have high-caliber speakers to share with us the latest breakthroughs and their visions in these fields. There will be two panel discussions focusing respectively on liquid biopsy and gene editing. Audience will have the great opportunities to ask questions, share ideas, learn from the experts, as well as to network with their peers.
REGISTERRegister Here

Program Highlights

  • Game-changing liquid biopsy assays for early cancer diagnostics
  • Applications of gene editing in target identification and drug screening
  • Development of cutting-edge gene therapies using CRISPR technology
  • Liquid biopsy in drug development and patient care
  • Showcase of success stories of artificial intelligence in disease diagnostics
  • Applications of artificial intelligence in addressing unmet medical needs

Program Agenda

8:20 – 8:45 Registration and Network

8:45 – 8:50 Welcome, Stephanie Shi, Ph.D., President of SABPA

8:50 – 9:00 FTD Opening Remarks, Hua Gong, MD, Ph.D., Chair FTD committee

Morning Session Chair, Hua Gong, MD, Ph.D., Chair of FTD committee

9:00 – 9:30 Keynote Presentation, Alex Aravanis, MD, Ph.D., Head of R&D, Grail, “Development of Early Cancer Detection Tests Based on Sequencing of Cell-Free Nucleic Acids“.

9:30 – 10:00 Presentation, Helmy Eltoukhy, Ph.D., CEO, Guardant health, “From Wired to Wireless: Current progress and future directions of liquid biopsies in oncology“.

10:00 – 10:30 Presentation, Wendy Winckler, Ph.D., Executive Director, Novartis, “Biomarkers of Response and Resistance in the Circulation“.

10:30 – 11:00 Coffee Break

11:00 – 12:10 Panel Discussion, “Liquid biopsy new development in Oncology diagnostics“. Moderator: Hatim Husain, MD.

  • Lyle Arnold, Ph.D., CSO, Biocept
  • Dongliang Ge, Ph.D., CEO, Apostle Inc
  • Hatim Husain, MD, Assistant Professor of Medicine, Moores Cancer Center, UCSD
  • Shidong Jia, Ph.D., CEO, PREDICINE
  • Traci Pawlowski, Ph.D., Senior Director Product Development, Oncology at Illumina

12:00 – 1:30 Lunch Break

Afternoon Session Chair, Howard Pan, Ph.D., Co-Chair of FTD committee

1:30 – 2:00 Presentation, Xiaohui Xie, Ph.D., Professor, UC Irvine, “Deep Learning in Genomics and Medicine”

2:00 – 2:30 Keynote Presentation, Michael White, Ph.D., VP, CSO, Pfizer Oncology R&D, “Harnessing cancer genome diversity for intervention target discovery“.

2:30 – 3:00 Presentation, Tony Ho, Ph.D., Head of Research and Development, CRISPR Therapeutics, “Bring CRISPR to the Clinic“.

3:00 – 3:30 Coffee Break

3:30 – 4:55 Panel Discussion, “Application of Novel Gene Editing Technologies in Drug Discovery and Development“. Moderator: Lawrence Lum, Ph.D.

  • Patrick D. Hsu, Ph.D., Principal Investigator, Salk Institute
  • Alexis C. Komor, Ph.D., Assistant Professor, Department of Chemistry and Biochemistry, UCSD
  • Lawrence Lum, Ph.D., Director, Cancer Systems Therapeutics, Pfizer Oncology R&D
  • Prashant Mali, Ph.D., Assistant Professor, Synthetic Biology, UCSD
  • Prasun Mishra, Ph.D., CEO, Agility Pharmaceuticals
  • Marco Weinberg, Ph.D., Research fellow, Vertex Pharmaceuticals

4:55 – 5:00 Closing Remarks, Peter Huang, Ph.D. EVP, SABPA

5:00 – 6:00 Cocktail Hours